AGO Research GmbH
AGO Research GmbH
Explore linked clinical trials.3 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer | Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma | Active, not recruiting | Phase 2 | 2026-05-13 | NCT04274426 | |
| Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, female reproductive system disorder, female reproductive system neoplasm, neoplasm, vulva cancer, vulvar disease | Recruiting | Phase 2 | 2026-05-11 | NCT05903833 | |
| WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, carcinoma, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 2 | 2025-10-03 | NCT04644289 |